RxDoctor Payments Data

Amy Miller

Gerontology · Hagerstown, MDNPI 1518545300

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.

$495in general payments, 2019–2025

Across 20 payments — averaging $24.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$118
  • E.r. Squibb & Sons, L.L.C.$73
  • Esperion Therapeutics, Inc.$50
  • Boehringer Ingelheim$43
  • Pfizer$41
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
  • plus $135 from 7 others

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$495 in reported general payments places this provider in the 60th percentile of 108 gerontology providers in Maryland.

See all gerontology providers in Maryland

Medicare billing

Part B allowed, 2024
$101,590
Medicare patients
577
Services billed
1,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,168$1,530,342
XareltoRivaroxaban368$437,354
EntrestoSacubitril/Valsartan128$151,771
Repatha SureclickEvolocumab52$58,067
FarxigaDapagliflozin Propanediol36$32,162
BrilintaTicagrelor26$29,797
JardianceEmpagliflozin17$20,905
Metoprolol Succinate890$16,781
Atorvastatin Calcium679$9,973
VascepaIcosapent Ethyl14$9,940
Diltiazem 24hr Er (Cd)Diltiazem Hcl250$8,010
Rosuvastatin Calcium299$6,258
Ezetimibe134$5,882
Metoprolol Tartrate737$5,522
Ranolazine ErRanolazine55$4,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$1,530,3421,168 claims
Johnson & JohnsonXarelto$26$437,354368 claims
Boehringer IngelheimJardiance$43$20,90517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 108 gerontology providers in Maryland.

Other gerontology in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →